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Impact of Outpatient vs Inpatient ABSSSI Treatment on Outcomes: A 
Retrospective Observational Analysis of Medical Charts Across US Emergency 
Departments 
Abstract 
Background 
The objective of this study was to characterize treatment of patients with acute bacterial skin and skin 
structure infections (ABSSSIs) and describe the association between hospital admission and emergency 
department (ED) visits or readmissions within 30 days after initial episode of care (IEC). 
Methods 
This was a retrospective, observational, cohort study of adults with ABSSSI who presented to an ED 
between July 1, 2012, and June 30, 2013. Patient, health care facility, and treatment characteristics, 
including unplanned ED visits or readmissions, were obtained through manual chart review and 
abstraction. Adjusted logistic regression analysis examined likelihood of all-cause unplanned ED visits or 
readmissions between admitted and nonadmitted patients. 
Results 
Records from 1527 ED visits for ABSSSI from 40 centers were reviewed (admitted, n = 578 [38%]; 
nonadmitted, n = 949 [62%]). Admitted patients were typically older (mean age, 52.2 years vs 43.0 years), 
more likely to be morbidly obese (body mass index > 40 kg/m2; 17.3% vs 9.1%), and had more 
comorbidities (Charlson Comorbidity Index ≥ 4; 24.4% vs 6.8%) compared with those not admitted. In the 
primary analysis, adjusted logistic regression, controlling for comorbidities and severity of illness, 
demonstrated that there was a similar likelihood of all-cause unplanned ED visits or readmissions 
between admitted and nonadmitted patients (odds ratio, 1.03; 95% confidence interval, 0.74–1.43; P = 
.87). 
Conclusions 
ABSSSI treatment pathways leveraging outpatient treatment vs hospital admission support similar 
likelihood of unplanned 30-day ED visits or readmissions, an important clinical outcome and quality 
metric at US hospitals. Further research regarding the decision criteria around hospital admission to 
avoid potentially unnecessary hospitalizations is warranted. 
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Background. The objective of this study was to characterize treatment of patients with acute bacterial skin and skin structure 
infections (ABSSSIs) and describe the association between hospital admission and emergency department (ED) visits or readmis-
sions within 30 days after initial episode of care (IEC).
Methods. This was a retrospective, observational, cohort study of adults with ABSSSI who presented to an ED between July 1, 
2012, and June 30, 2013. Patient, health care facility, and treatment characteristics, including unplanned ED visits or readmissions, 
were obtained through manual chart review and abstraction. Adjusted logistic regression analysis examined likelihood of all-cause 
unplanned ED visits or readmissions between admitted and nonadmitted patients.
Results. Records from 1527 ED visits for ABSSSI from 40 centers were reviewed (admitted, n = 578 [38%]; nonadmitted, n = 949 
[62%]). Admitted patients were typically older (mean age, 52.2 years vs 43.0 years), more likely to be morbidly obese (body mass 
index > 40 kg/m2; 17.3% vs 9.1%), and had more comorbidities (Charlson Comorbidity Index ≥ 4; 24.4% vs 6.8%) compared with 
those not admitted. In the primary analysis, adjusted logistic regression, controlling for comorbidities and severity of illness, demon-
strated that there was a similar likelihood of all-cause unplanned ED visits or readmissions between admitted and nonadmitted 
patients (odds ratio, 1.03; 95% confidence interval, 0.74–1.43; P = .87).
Conclusions. ABSSSI treatment pathways leveraging outpatient treatment vs hospital admission support similar likelihood of 
unplanned 30-day ED visits or readmissions, an important clinical outcome and quality metric at US hospitals. Further research 
regarding the decision criteria around hospital admission to avoid potentially unnecessary hospitalizations is warranted.
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Acute bacterial skin and skin structure infections (ABSSSIs), or 
complicated skin and soft tissue infections (cSSTIs), include a range 
of skin and skin structure infections, such as cellulitis/erysipelas, 
wound infections, and major cutaneous abscesses. Gram-positive 
pathogens, including Staphylococcus aureus (both methicillin-re-
sistant [MRSA] and methicillin-sensitive strains) and Streptococcus 
pyogenes, are the most common cause of culture-positive ABSSSI 
[1–3]. Less frequently, other Streptococcus spp., Enterococcus faeca-
lis, or Gram-negative bacteria are implicated.
Acute bacterial skin and skin structure infections are a common 
reason for emergency department (ED) visits [4, 5]. Although 
guidelines were developed that support outpatient management 
of ABSSSIs for appropriate patients [6], hospital admissions in the 
United States due to primary diagnosis of skin and skin structure 
infections increased from 1.6% in 2005 to 2.0% of patients in 2011 
[7]. Furthermore, institutional consistency and guidelines have 
not yet been optimized; clinician practices regarding the decision 
to provide outpatient or inpatient treatment may vary greatly even 
within a single institution [8, 9]. Although hospital admission may 
be a strategy that is used in an effort to ensure optimal outcomes, 
whether admission improves outcomes requires further investiga-
tion [9, 10]. This is especially true because antibiotic stewardship 
programs that leverage outpatient treatment pathways and novel 
antibiotic therapy may affect treatment strategy, improve patient 
outcomes, and reduce costs [11–13].
This study describes the patient, health care facility, and treat-
ment characteristics of those with ABSSSIs and the likelihood 
of unplanned 30-day ED visits or readmissions among patients 
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who were admitted vs patients who were not admitted to the 
hospital after their initial ED visit. The main purpose of this 
study was to evaluate whether treatment location (ie, hospital 
admission vs outpatient treatment) was a predictor of unplanned 
30-day ED visits or readmissions after initial ABSSSI treatment.
METHODS
Study Design and Study Setting
This was a retrospective, observational cohort study of adult 
patients with ABSSSI who presented to an ED between July 1, 
2012, and June 30, 2013, across 40 ED sites in the United States. 
Each institution developed a systematic process to identify ≥30 
patients meeting study eligibility criteria. Of those patients, at 
least 10% were required to have been admitted to the hospital. 
The initial episode of care (IEC) was defined as the initial hos-
pital or ED visit up to the point of hospital or ED discharge. As a 
result, it is possible that a patient could have spent multiple days 
in the ED before discharge.
All collected data were obtained by manual medical chart 
review and were de-identified before collation to comply with 
current Health Insurance Portability and Accountability Act of 
1996 (HIPAA) regulations. Institutional review board approval 
was obtained for each site. Patient consent was not required due 
to the retrospective nature of the study. The study met the eth-
ical principles of the Declaration of Helsinki.
The study was sponsored by Allergan plc (Dublin, Ireland). 
Because most authors were employees of Allergan at the time 
of study conduct and analysis, the study sponsor was involved 
in the study design, conduct, and analysis and in critical review 
and approval of the manuscript.
Study Population
Adult patients aged ≥18  years were included if they had an 
ED diagnosis with ≥1 relevant International Classification of 
Diseases (ICD)-9 codes: 681.XX (cellulitis and abscess of fin-
ger and toe), 682.XX (other cellulitis and abscess), 686.XX 
(other local infections of skin and subcutaneous tissue), 958.3X 
(posttraumatic wound infection—not elsewhere classified), or 
998.5X (postoperative infection—not elsewhere classified) [7].
Patients were excluded if they had a diagnosis of necrotizing 
fasciitis (ICD-9 code: 728.86), gas gangrene (040.0), or gan-
grene (785.6), as these severe infections are not consistent with 
the definition of ABSSSI [1]. Patients were excluded if there 
was any evidence of fungal infection (alone or in combination 
with a bacterial infection) or if the ABSSSI was solely due to 
Gram-negative bacteria defined microbiologically. Patients 
with known or suspected HIV infection and a CD4 count <200 
cells/mm3, or with past or current AIDS-defining condition and 
unknown CD4 count, were also excluded.
Key Outcome Measures
Patient, health care facility, and treatment characteristics, 
including unplanned ED visits or hospitalizations within 30 days 
of the IEC, were obtained through manual chart review and the 
abstraction process. Patient-level data were de-identified at the 
source and aggregated into a single database for analysis.
Patient and Health Care Facility Characteristics 
Patient demographics and clinical characteristics that were col-
lected included age, sex, skin infection type, body mass index 
(BMI), Charlson Comorbidity Index (CCI), health insurance 
type, Systemic Inflammatory Response Syndrome (SIRS) crite-
ria (≥2 criteria: temperature >38°C [100.4°F] or <36°C [96.8°F]; 
heart rate >90 beats/minute; respiratory rate ≥20 breaths/min-
ute or partial carbon dioxide pressure [PaCO2] ≤32  mmHg; 
white blood cell count [WBC] ≥12 000/mm
3 or ≤4000/mm3; 
and suspected or proven infection), history of ABSSSI within 
30  days, hospitalization within 90  days, known history of 
MRSA, systemic antibiotic use within 90 days of IEC, and cur-
rent or past intravenous drug use [IVDU]). Patients were classi-
fied as admitted at the IEC if they were admitted as an inpatient 
to an intensive care unit (ICU), a unit other than the ICU, or 
transferred to another hospital. Patients were classified as not 
admitted at the IEC if they were transferred to an observational 
bed/unit (from a resource use perspective, these patients are 
not considered admitted), discharged to their home, left the ED 
against medical advice, transferred to a skilled nursing facility 
or long-term care, or if they died before any admission or dis-
charge proceeding.
Health care facility characteristics included geographic 
region, hospital organization type (academic vs commu-
nity), bed capacity, hospital observation unit status (dedicated 
observation unit vs interspersed throughout hospital), hos-
pital-owned outpatient infusion center affiliation, integrated 
delivery system affiliation, accountable care organization affili-
ation, and number of full-time equivalents for antibiotic over-
sight/stewardship in the ED.
Treatment Characteristics
Treatments for ABSSSI received during the IEC and at dis-
charge were described, including whether a lesion culture was 
obtained, whether an incision and drainage were performed, 
or whether a peripherally inserted central catheter (PICC) was 
placed. Antibiotic therapy received during the IEC and at dis-
charge was recorded. Antibiotic therapy was classified as rec-
ommended or not recommended (Supplementary Table 1) by 2 
investigators (P. Brandon Bookstaver and Timothy C. Jenkins) 
based on the Infectious Diseases Society of America (IDSA) 
guidelines for empiric skin and soft tissue infection treatment 
[14–16]. The duration of antibiotic therapy and the most com-
mon therapies at the IEC and at discharge were described [14].
Unplanned 30-Day ED Visits or Readmissions
Patients who had an unplanned visit to the ED or hospitaliza-
tion for any cause within 30 days of IEC discharge were defined 
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as experiencing an unplanned 30-day ED visit or readmission. 
In addition to all-cause unplanned 30-day ED visits or read-
missions, skin infection–related unplanned 30-day ED visits or 
readmissions were assessed.
Data Analysis
Descriptive statistics were conducted on the patient, health 
care facility, and treatment characteristics using counts and 
percentages for categorical variables and means and standard 
deviations for continuous variables. Both all-cause and skin 
infection–related unplanned 30-day ED visits or readmissions 
were similarly described.
Unadjusted (ie, univariate) and multivariate logistic regres-
sion with adjustment for confounding variables were used to 
estimate the likelihood of both all-cause and skin infection–
related unplanned 30-day ED visits or readmissions comparing 
patients who were admitted and those who were not admitted 
to the hospital. In accordance with causal inference methodol-
ogy, all variables chosen for logistic regression models occurred 
before the decision to admit or not admit was expected to be 
made. The outcome for all-cause unplanned 30-day ED visits 
or readmissions was used as our primary analysis, as it has been 
assessed previously as an important clinical outcome and part 
of hospital quality assessment, whereas the outcome for skin 
infection–related unplanned 30-day ED visits or readmissions 
was used as a secondary analysis. For the primary and sec-
ondary analyses, variables were selected for adjustment using 
stepwise logistic regression (Model 1); additional variables were 
selected to include a second model based on clinical and epi-
demiologic rationale (Model 2). For the initial stepwise logistic 
regression (Model 1), variables that met the threshold (P ≤ .30) 
were utilized based on univariate analyses. Forward stepwise 
selection determined the final models. The primary predictor 
variable (admission status after the IEC) was forced into the 
stepwise logistic regression analysis for the final model.
Missing data were not imputed; thus, analyses were under-
taken using available data only. Statistical significance was 
defined as P < .05. All analyses were conducted using SAS sta-
tistical software (SAS, version 9.3; SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
In total, records from 1527 patients with ED visits for ABSSSIs 
from 40 centers were included in the analysis: 37.9% of patients 
(578/1527) were admitted to the hospital at the IEC, whereas 
62.1% (949/1527) were not admitted at the IEC (Figure  1). 
Among admitted patients, 547/578 (94.6%) were non-ICU 
admissions, 29/578 (5.0%) were admitted to the ICU, and 2/578 
(0.3%) were transferred to another hospital or destination was 
not specified. Of the patients who were not admitted, 894/949 
(94.2%) were discharged home, 38/949 (4.0%) were transferred 
to an observation bed/unit, 9/949 (0.9%) departed against med-
ical advice, and 8/949 (0.8%) were transferred to a skilled nurs-
ing facility or long-term care. Patient demographics and clinical 
characteristics are shown in Table 1. Patients who were admitted 
were older (mean age, 52.2 years vs 43.0 years), were more likely 
to be morbidly obese (BMI > 40 kg/m2; 17.3% vs 9.1%), and had 
more comorbidities (CCI ≥4; 24.4% vs 6.8%). The majority of the 
overall cohort presented with cellulitis (50.4%) and had evidence 
of limited comorbidity (CCI 0 or 1; 52.1% admitted patients vs 
84.1% nonadmitted patients). Admitted patients exhibited a 
greater severity of infection (as assessed by the presence of SIRS; 
32.7% vs 5.6%) than those who were not admitted.
Admitted to hospital
n = 578/1527 (37.9%)a
Patients presenting to ED for IEC
n = 1527
Total unplanned ED
visits or readmissions
n = 140/578 (24.2%)b
Skin infection–related
ED visits or readmissions
n = 70/578 (12.1%)b
Not admitted to hospital
n = 949/1527 (62.1%)a
Total unplanned ED
visits or readmissions
n = 204/949 (21.5%)b
Skin infection–related
ED visits or readmissions
n = 123/949 (13.0%)b
Figure 1. Treatment pathway following the ED visit for the IEC and unplanned 30-day ED visits or readmissions. aAn unplanned ED visit or readmission is an unplanned visit 
to the ED or an unplanned hospital admission within 30 days of discharge from the ED or hospital after the IEC. bIndicates percentage of patients from the total subgroup in 
the arm of treatment pathway. Abbreviations: ED, emergency department; IEC, initial episode of care.
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Table 1. Patient and Treatment Characteristics Stratified by Admission Status
Admitted (n = 578; 37.9%) Not Admitted (n = 949; 62.1%) Total (n = 1527)
Patient characteristic
Mean (±SD) age,a y 52.2 (±17) 43.0 (±17) 46.5 (±18)
Sex, n (%)
 Male 315 (54.5) 506 (53.3) 821 (53.8)
Skin infection type,a,b n (%)
 Cellulitis 332 (57.4) 437 (46.1) 769 (50.4)
 Major abscess 160 (27.6) 407 (42.9) 567 (37.1)
 Surgical site infection or traumatic wound 81 (14.0) 92 (9.7) 173 (11.3)
BMI,a,b n (%)
 <30 kg/m2 283 (49.0) 423 (44.6) 706 (46.2)
 30–40 kg/m2 173 (29.9) 286 (30.1) 459 (30.1)
 >40 kg/m2 100 (17.3) 86 (9.1) 186 (12.2)
CCI score,a n (%)
 0 174 (30.1) 650 (68.5) 824 (54.0)
 1 127 (22.0) 148 (15.6) 275 (18.0)
 2 62 (10.7) 74 (7.8) 136 (8.9)
 3 74 (12.8) 12 (1.3) 86 (5.6)
 4+ 141 (24.4) 65 (6.8) 206 (13.5)
Health insurance type,a,b n (%)
 Commercial 164 (28.4) 256 (27.0) 420 (27.5)
 Medicaid 84 (14.5) 163 (17.2) 247 (16.2)
 Medicare 126 (21.8) 93 (9.8) 219 (14.3)
 Self-pay 103 (17.8) 282 (29.7) 385 (25.2)
 Othersc 80 (13.8) 98 (10.3) 178 (11.7)
Met initial SIRS criteria,a,b,d n (%) 189 (32.7) 53 (5.6) 242 (15.9)
History of ABSSSI within 30 d before IEC,a,b n (%) 137 (23.7) 103 (10.9) 240 (15.7)
Hospitalization within 90 d before IEC,a,b n (%) 169 (29.2) 99 (10.4) 268 (17.6)
Known history of MRSA, n (%)a,b 91 (15.7) 78 (8.2) 169 (11.1)
Systemic antibiotic use within 90 d before admission,a,b n (%) 238 (41.2) 194 (20.4) 432 (28.3)
Current/past IVDU,a,b n (%) 73 (12.6) 57 (6.0) 130 (8.5)
Treatment characteristic
Lesion culture obtained,a,b,e n (%) 283 (49.0) 187 (19.7) 470 (30.8)
 Gram-positive culturef 198/283 (70.0) 136/187 (72.7) 334/470 (71.1)
 MRSAg 108/198 (54.6) 64/136 (47.1) 172/334 (51.5)
Incision and drainage performed on abscess,a n (%) 204 (35.3) 362 (38.2) 566 (37.1)
PICC insertion,a,b n (%) 96 (16.6) 6 (0.6) 102 (6.7)
Antibiotic therapy at IEC
Antibiotic therapy at IEC,a n (%) 568 (98.3) 451 (47.5) 1019 (66.7)
Receipt of guideline-recommended antibiotic therapy during IEC,h,i n (%)
 IDSA only 205 (36.1) 355 (77.7) 560 (55.0)
 Non-IDSA only 50 (8.8) 55 (12.2) 105 (10.3)
 Both IDSA and non-IDSAj 313 (55.1) 41 (9.1) 354 (34.7)
Antibiotic therapy at discharge
Antibiotic therapy at discharge,a n (%) 476 (82.4) 848 (89.4) 1324 (86.7)
Receipt of guideline-recommended antibiotic therapy at discharge,h,i n (%)
 IDSA only 301 (63.2) 780 (92.0) 1081 (81.7)
 Non-IDSA only 116 (24.4) 47 (5.5) 163 (12.3)
 Both IDSA and non-IDSAj 59 (12.4) 21 (2.5) 80 (6.0)
Abbreviations: ABSSSI, acute bacterial skin and skin structure infection; BMI, body mass index; CCI, Charlson Comorbidity Index; ED, emergency department; IDSA, Infectious Diseases 
Society of America; IEC, initial episode of care; IVDU, intravenous drug use; MRSA, methicillin-resistant Staphylococcus aureus; PICC, peripherally inserted central catheter; SIRS, systemic 
inflammatory response syndrome.
aStatistically significant difference between those admitted and those not admitted after the initial visit to the ED (P < .05). 
bData not available for all patients; percentage was calculated using total patients in that category (ie, admitted, not admitted, or total) as the denominator. 
cIncludes those with ≥2 insurance types and those with Tricare.
dPatients not admitted were not given a full set of vital signs and/or laboratory tests.
eInfections solely due to Gram-negative bacteria were excluded (applies to whole analysis, per exclusion criteria in the “Methods”). 
fThe percentage of patients was calculated from those patients for whom a lesion culture was obtained. 
gThe percentage of patients was calculated from those patients for whom a Gram-positive culture was obtained. 
hThe percentage of patients was calculated from those patients given antibiotic treatment. 
iStatistical analysis testing was not performed for this variable. 
jIncludes patients whose antibiotic was recorded as an antifungal or “other” during the IEC and at discharge.
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Health Care Facility Characteristics
Included patients were primarily from facilities located in 
the South (43.4% of patients) or Midwest (27.8% of patients) 
geographic regions of the United States, a majority of which 
were academic medical centers (66.0% of patients) (Table  2; 
Supplementary Figure  1). Participating centers from the 
Midwest or Northeast regions of the United States and hospitals 
affiliated with an Integrated Delivery Network or Accountable 
Care Organization included more admitted patients in the 
study than other centers. Patients were less likely to be admitted 
if they presented at an ED with antibiotic oversight/stewardship 
activities (42% vs 49%).
Treatment Characteristics
Mean (±SD) time spent in the ED was 0.3 ± 2.5 days (7.6 ± 59.7 
hours); admitted patients had a mean (±SD) length of hospital 
stay of 5.5  ±  7.3  days (132  ±  175 hours). Treatment charac-
teristics were stratified by admission status and are shown in 
Table 1. Admitted patients were significantly more likely to have 
a culture obtained from a lesion during the IEC when com-
pared with patients who were not admitted (49.0% [283/578] 
vs 19.7% [187/949]). Admitted patients were significantly 
more likely to either have a PICC line placed (16.6% vs 0.6%; 
P < .05) or be given antibiotic therapy during the IEC (98.3% vs 
47.5%; P < .05) compared with nonadmitted patients. Of those 
patients, a significantly greater percentage of admitted patients 
received non-IDSA-recommended antibiotic therapy in con-
junction with empirical IDSA-recommended antibiotic therapy 
at the IEC when compared with patients who were not admitted 
(55.1% vs 9.1%; P  <  .05). There was no significant difference 
in the percentage of patients that received antibiotic therapy at 
Table 2.  Health Care Facility Characteristics Stratified by Admission Status
Health Care Facility Characteristic
Admitted
(n = 578; 37.9%), n (%)
Not Admitted 
(n = 949; 62.1%), n (%)
Total  
(n = 1527), n (%)
Geographic regiona
 Midwest 209 (36.2) 216 (22.8) 425 (27.8)
 Northeast 94 (16.3) 84 (8.9) 178 (11.7)
 South 204 (35.3) 458 (48.3) 662 (43.4)
 West 71 (12.3) 191 (20.1) 262 (17.2)
Hospital/organization type
 Academic medical center 396 (68.5) 611 (64.4) 1007 (66.0)
 Community 182 (31.5) 338 (35.6) 520 (34.1)
Bed capacity, No. of bedsa
 <250 21 (3.6) 55 (5.8) 76 (4.9)
 250–399 37 (6.4) 83 (8.8) 120 (7.9)
 400–749 346 (59.9) 572 (60.3) 918 (60.1)
 ≥750 174 (30.1) 239 (25.2) 413 (27.1)
Hospital observation unit statusa,b
 Dedicated observation unit 345 (59.7) 473 (49.8) 818 (53.6)
 Interspersed throughout hospital 176 (30.5) 357 (37.6) 533 (34.9)
Hospital-owned outpatient infusion center affiliationa,b
 Yes 444 (76.8) 667 (70.3) 1111 (72.8)
 No 108 (18.7) 250 (26.3) 358 (23.4)
Integrated delivery system affiliationa,b
 Yes 271 (46.9) 338 (35.6) 609 (39.9)
 No 100 (17.3) 232 (24.5) 332 (21.7)
Accountable care organization affiliationa,b
 Yes 394 (68.2) 516 (54.4) 910 (59.6)
 No 73 (12.6) 273 (28.8) 346 (22.7)
Antibiotic oversight/stewardship activities in the EDa,b
 Yes 245 (42.4) 467 (49.2) 712 (46.6)
 No 319 (55.2) 468 (49.3) 787 (51.5)
No. of FTEs for antibiotic oversighta,b
 0 17 (2.9) 42 (4.4) 59 (3.9)
 >0–1 172 (29.8) 431 (45.4) 603 (39.5)
 >1–2 174 (30.1) 222 (23.4) 396 (25.9)
 >2–3 66 (11.4) 87 (9.2) 153 (10.0)
 >3–4 36 (6.2) 9 (0.95) 45 (2.9)
Abbreviations: ED, emergency department; IEC, initial episode of care; FTE, full-time equivalent. 
aStatistically significant difference between those admitted and those not admitted after the initial visit to the ED (P < .05). 
bData on facility characteristics were not available for all patients.
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discharge between admitted and nonadmitted patients (82.4% 
vs 89.4%). The majority of both admitted and nonadmitted 
patients received IDSA-recommended antibiotic therapy at 
discharge, without concomitant antibiotic therapy that is not 
recommended by the IDSA (63.2% vs 92.0%, respectively). The 
most common antibiotic treatments administered to patients 
at the IEC and discharge are shown in Supplementary Table 2. 
Admitted patients received intravenous (IV) vancomycin most 
commonly at the IEC and oral trimethoprim/sulfamethoxazole 
at discharge; nonadmitted patients most commonly received 
oral trimethoprim/sulfamethoxazole at the IEC and discharge. 
Of note, admitted patients were more likely to have had a his-
tory of ABSSSI within 30 days before the IEC (23.7% vs 10.9%), 
hospitalization within 90 days before the IEC (29.2% vs 10.4%), 
and a history of MRSA (15.7% vs 8.2%).
The mean (±SD) durations of antibiotic therapy during the 
IECs of admitted and nonadmitted patients were 5.8 ± 4.8 days 
and 2.0 ± 2.7 days, respectively (P < .05) (Figure 2). The mean 
(±SD) durations of antibiotic therapy at discharge of admit-
ted and nonadmitted patients were 13.8  ±  15.4  days and 
10.6  ±  4.7  days, respectively (P  <  .05) (Figure  2). The mean 
(±SD) total duration of antibiotic therapy, including both IEC 
and discharge antibiotics, was significantly longer for those who 
were admitted vs those who were not admitted (19.4 ± 16.9 days 
vs 12.8 ± 5.5 days; P < .05) (Figure 2).
Unplanned 30-Day ED Visits or Readmissions
The proportion of patients experiencing all-cause unplanned 
ED visits or readmissions to the ED or hospital within 30 days 
was similar for admitted vs nonadmitted patients (24.2% 
[140/578] vs 21.5% [204/949]) and for patients experiencing 
skin infection–related unplanned ED visits or readmissions 
(12.1% [70/578] vs 13.0% [123/949]) (Figure 1).
All-Cause Unplanned ED Revisits or Readmissions
For the primary analysis (Figure 3), unadjusted logistic regres-
sion demonstrated that there was similar likelihood of all-cause 
unplanned 30-day ED visits or readmissions between admitted 
and nonadmitted patients (odds ratio [OR],  1.17; 95% confi-
dence interval [CI], 0.91–1.49; P = .22). For the adjusted logistic 
regression for the primary analysis using Model 1 and adjusted 
for covariates* (described in Supplementary Table 3), admission 
status at the IEC was not significantly associated with all-cause 
unplanned 30-day ED visits or readmissions (OR,  1.03; 95% 
CI, 0.74–1.43; P =  .87). Admission status at the IEC was also 
not significantly associated with all-cause unplanned ED visits 
or readmissions (OR, 1.02; 95% CI, 0.46–2.22; P =  .97) using 
Model 2, which was adjusted for additional clinically relevant 
covariates† (described in Supplementary Table 3).
*Model 1 covariates: admission status at the IEC; BMI; 
hospitalization within 90  days before this admission; 
known history of MRSA, including colonization; hospital 
type (community, academic medical center); accountable 
care organization affiliation.
†Model 2 was adjusted for the covariates in Model 1, along 
with additional clinically relevant covariates: age; health 
insurance type; sex; geographical location; CCI; current/
past IV drug use; history of ABSSSI within 30 days; sys-
temic antibiotic use within 90 days before this admission; 
met initial SIRS criteria; infection type; patient dispos-
ition; hospital-owned outpatient facility; number of full-
time equivalents for antibiotic oversight; bed capacity; 
incision and drainage performed on abscess; receipt of 
antibiotic therapy; pathogen was cultured.
Skin Infection–Related Unplanned ED Revisits or Readmissions
Similar results were supported for the secondary analysis 
assessing the likelihood of skin infection–related unplanned 
30-day ED visits or readmissions (OR, 0.93; 95% CI, 0.68–1.27; 
P = .63) (Figure 3). For the adjusted logistic regression for the 
secondary analysis, admission status was not statistically asso-
ciated with skin infection–related unplanned 30-day ED visits 
or readmissions (OR, 0.52; 95% CI, 0.25–1.12; P =  .10) using 
Model 1 adjusted for covariates‡ (described in Supplementary 
Table 4). However, after adjusting for additional clinically rele-
vant covariates (Model 2),§ results supported a decreased likeli-
hood of skin infection–related 30-day ED visits or readmissions 
among admitted vs nonadmitted patients (OR,  0.36; 95% CI, 
0.13–0.96; P = .04). Among clinically relevant covariates, none 
were individually found to be significant; the combination of 
covariates likely drove significance, rather than 1 covariate.
‡Model 1 covariates: admission status at the IEC; BMI; 
CCI; history of ABSSSI within 30 days; known history of 
MRSA, including colonization; met initial SIRS criteria; 
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Figure 2. Duration of antibiotic treatment. Abbreviation: IEC,  initial episode of 
care.
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infection type; hospital geographical location; accountable 
care organization affiliation; patient disposition; incision 
and drainage performed on abscess.
§Model 2 was adjusted for the covariates in Model 1, along 
with additional clinically relevant covariates: age; health 
insurance type; sex; current/past IV drug use; hospital-
ization within 90  days before this admission; systemic 
antibiotic use within 90 days before this admission; hos-
pital type (community, academic medical center); hos-
pital-owned outpatient facility; number of full-time 
equivalents for antibiotic oversight; bed capacity; receipt 
of antibiotic therapy; pathogen was cultured.
DISCUSSION
Our results support a similar likelihood of unplanned 30-day 
ED visits or readmissions among patients admitted to the hos-
pital for ABSSSI treatment vs patients who received outpatient 
treatment, after controlling for patient characteristics and 
severity of illness. It is the largest observational study to date 
in an ABSSSI patient population presenting to EDs, describing 
ABSSSI treatment and clinical outcomes for 1527 patients across 
40 US EDs. Because we found similar outcomes among admit-
ted vs nonadmitted patients, our results highlight the need for 
improved transitions of care to the outpatient setting to prevent 
unnecessary or prolonged inpatient care.
The current treatment paradigm for ABSSSI has included 
routine hospital admission for the purpose of delivering IV 
antibiotic therapy for patients, as no standard criteria have been 
developed to assist clinicians with the decision of who should 
be admitted for advanced care [17]. Hospital admission may be 
required to provide appropriate care for ABSSSI patients with 
septic shock, complicating comorbid conditions, or those at risk 
of acute deterioration. However, unnecessary hospitalizations 
place patients at increased risk for adverse events and hospi-
tal-acquired infections, are economically burdensome, and may 
not be associated with optimal outcomes [3, 18]. In addition, 
hospital readmissions have come under the spotlight as critical 
measures in hospital outcomes and are tied to hospital reim-
bursement [11, 19].
Our primary results support that hospital admission, com-
pared with discharge from the ED, may not affect the likelihood 
Unadjusted analysis
Model 1a
Model 1a
Model 2b
Model 2b
0.1 1 10
Favors hospital admission
All-cause unplanned ED visits or readmissions
Skin infection–related unplanned ED visits or readmissions
Analysis OR (95% CI) P Value
All-cause unplanned ED visits or readmissions
Skin infection–related unplanned ED visits or readmissions
Unadjusted analysis
Model 1: Stepwise logistic regression
Model 1: Stepwise logistic regression
Model 2: Addition of clinically relevant variables to Model 1
Model 2: Addition of clinically relevant variables to Model 1
Unadjusted analysis
1.17 (0.91–1.49)
1.03 (0.74–1.43)
0.52 (0.25–1.12)
1.02 (0.46–2.22)
0.36 (0.13–0.96)
0.93 (0.68–1.27)
.22
.87
.10
.97
.04
.63
Favors discharge from ED
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Figure 3. Logistic regression models: likelihood of all-cause and skin infection–related unplanned 30-day ED visit or readmission. aModel 1 was the stepwise logistical 
regression analysis and included the covariates listed in Supplementary Tables 3 and 4 under Model 1. bModel 2 included the addition of clinically relevant variables and 
included the covariates listed in Supplementary Tables 3 and 4 under Model 2. Abbreviations: ABSSSI, acute bacterial skin and skin structure infection; CI, confidence interval; 
ED, emergency department; OR, odds ratio.
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of all-cause unplanned 30-day ED visits or readmissions, an 
important clinical outcome and quality metric for US hospitals. 
These study results may help to reassure clinicians that outpa-
tient management for ABSSSI does not necessarily result in a 
higher likelihood of follow-up care within 30 days of the initial 
ED presentation. Focusing on identifying the appropriate crite-
ria for hospital admissions and integrating these criteria into care 
pathways should reduce or prevent readmissions. However, fur-
ther research is warranted, specifically for skin infection–related 
ED visits or readmissions, to identify significant predictors of 
follow-up care. In 1 of the 4 regression models, patients who 
were admitted were significantly less likely to receive skin infec-
tion–related follow-up care. Although the other 3 models were 
not significant in this comparison, these results further support 
the opportunity to improve outpatient care pathways in addition 
to identifying appropriate criteria for hospital admission criteria.
Improving antibiotic stewardship practices in the ED to 
optimize antibiotic therapy and assist in transitions of care 
is important. The substantial amount of non–IDSA guide-
line–concordant antibiotic therapy in the admitted group 
and the extended duration of antibiotic therapy in both the 
admitted and nonadmitted populations highlight the need for 
ongoing antibiotic stewardship among patients with ABSSSI. 
Augmenting hospital- and ED-based antibiotic stewardship 
programs or the development and integration of care pro-
cess models would be 2 methods to reduce unnecessarily 
broad-spectrum antibiotic use and total duration of ther-
apy [20, 21]. Antibiotic stewardship comprises “coordinated 
intervention programs” designed to improve and measure 
the appropriate use of antibiotic agents by promoting empiric 
selection of the optimal antibiotic drug regimen (eg, dosing, 
duration of therapy, and route of administration) [22]. These 
programs have been shown to reduce inappropriate anti-
biotic use, conserve resources, optimize treatment duration, 
decrease treatment-related adverse events, and improve the 
rates of antibiotic susceptibilities to targeted antibiotics [9, 
23–25]. Failure to use antibiotics that are guideline-recom-
mended or use of inappropriate antibiotics, such as the use 
of broad-spectrum antibiotics for most cases of ABSSSI, is 
associated with increasing drug resistance, adverse events, 
and other unintended consequences including Clostridium 
difficile infection [26, 27]. Although these programs have pri-
marily been used in the inpatient setting, antibiotic steward-
ship programs also play a role in EDs [23, 24]. Furthermore, 
novel antibiotic therapies such as long-acting parenteral anti-
biotics may offer an alternative outpatient therapy in patients 
where complicating factors do not necessitate hospitalization 
yet require IV therapy. Long-acting therapy could reduce tra-
ditional institutional barriers to coordinating outpatient treat-
ment, facilitating improved stewardship practices [20, 21, 28].
This study is not without limitations. The lack of randomiza-
tion may have contributed to selection bias. Data were collected 
through manual review of medical records, where the process 
may have imparted subjectivity or misclassification of ABSSSI. 
The primary analysis was completed using available data; 
missing information was not imputed. In our comparison of 
unplanned 30-day ED visits or readmissions with the primary 
predictor variable of admission status, we controlled for multiple 
clinical variables in our model but did not perform a propensity 
score–matched analysis. Despite adjusting for many confound-
ing variables, there may be residual confounding because 
admitted and nonadmitted patients likely have additional clin-
ically important differences not captured in this study. Patients 
who died also could not be included for an unplanned 30-day 
ED visit or readmission. However, because the number was low 
(n = 2; <1%), those patients were not excluded from the overall 
calculations, which was not expected to substantially affect the 
results. Another limitation was that patients may have visited 
a different ED or hospital that was not captured in our data 
set. Although we cannot determine the number of patients for 
whom this circumstance would apply, the Healthcare Cost and 
Utilization Project [29] has estimated the all-cause readmission 
across US hospitals to be 11.2% [29]. Because the percentage 
of readmission in this study was 22% for admitted patients and 
24% for patients not admitted, we do not believe that this limi-
tation severely affected our study. Furthermore, the percentage 
of readmission in this study was similar to previously reported 
estimates of 30-day readmissions among patients presenting to 
the ED with a skin and soft tissue infection [30]. Because of 
the study design, we were unable to determine causality regard-
ing why certain groups of hospitals (centers from the Midwest 
and Northeast regions of the United States and hospitals affili-
ated with an Integrated Delivery Network or Accountable Care 
Organization) included more admitted patients in the study 
than other centers or why patients were less likely to be admit-
ted if they presented at an ED with antibiotic oversight/stew-
ardship activities.
CONCLUSIONS
Acute bacterial skin and skin structure infection treatment 
pathways leveraging outpatient treatment vs hospital admission 
support similar likelihood of unplanned 30-day ED visits or 
readmissions, an important clinical outcome and quality metric 
at US hospitals. Further research regarding the decision criteria 
around hospital admission, as well as implementation of anti-
biotic stewardship programs to facilitate transitions of care, is 
warranted to avoid potentially unnecessary or prolonged hos-
pital stays.
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